Aethlon Medical Appoints New Auditor
Ticker: AEMD · Form: 8-K · Filed: Jul 3, 2024 · CIK: 882291
| Field | Detail |
|---|---|
| Company | Aethlon Medical Inc (AEMD) |
| Form Type | 8-K |
| Filed Date | Jul 3, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, accounting
TL;DR
Aethlon Medical switches auditors from BDO to CohnReznick, effective immediately.
AI Summary
Aethlon Medical, Inc. announced on July 1, 2024, that it has appointed a new independent registered public accounting firm, CohnReznick LLP, effective immediately. This change follows the resignation of its previous auditor, BDO USA, LLP. The company stated that the decision was not a result of any disagreements with BDO USA, LLP.
Why It Matters
A change in auditors can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting, which investors will monitor.
Risk Assessment
Risk Level: low — This filing is a routine change of auditor and does not involve any financial transactions or operational changes.
Key Players & Entities
- Aethlon Medical, Inc. (company) — Registrant
- CohnReznick LLP (company) — New independent registered public accounting firm
- BDO USA, LLP (company) — Former independent registered public accounting firm
- July 1, 2024 (date) — Effective date of auditor change
FAQ
Who is Aethlon Medical, Inc.'s new independent registered public accounting firm?
Aethlon Medical, Inc.'s new independent registered public accounting firm is CohnReznick LLP.
When was the change in auditor effective?
The change in auditor was effective immediately as of July 1, 2024.
Who was Aethlon Medical, Inc.'s previous auditor?
Aethlon Medical, Inc.'s previous auditor was BDO USA, LLP.
Were there any disagreements between Aethlon Medical, Inc. and its former auditor?
No, Aethlon Medical, Inc. stated that the decision to change auditors was not a result of any disagreements with BDO USA, LLP.
What is the filing date of this 8-K report?
This 8-K report was filed on July 3, 2024.
Filing Stats: 964 words · 4 min read · ~3 pages · Grade level 14.3 · Accepted 2024-07-03 16:27:48
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share AEMD The Nasdaq
Filing Documents
- aethlon_8k.htm (8-K) — 31KB
- aethlon_ex1601.htm (EX-16.1) — 4KB
- image_005.jpg (GRAPHIC) — 4KB
- image_003.jpg (GRAPHIC) — 7KB
- 0001683168-24-004660.txt ( ) — 222KB
- aemd-20240701.xsd (EX-101.SCH) — 3KB
- aemd-20240701_lab.xml (EX-101.LAB) — 33KB
- aemd-20240701_pre.xml (EX-101.PRE) — 22KB
- aethlon_8k_htm.xml (XML) — 4KB
01
Item 4.01 Changes in Registrant's Certifying Accountant Dismissal of Independent Registered Public Accounting Firm On July 1, 2024, Aethlon Medical, Inc. ( the "Company") dismissed Baker Tilly US, LLP ("Baker Tilly") as the Company's independent registered public accounting firm effective as of that date. The board of directors of the Company (the "Board") approved the dismissal of Baker Tilly on July 1, 2024, based upon the recommendation of the audit committee of the Board (the "Audit Committee"). The report of Baker Tilly as of and for the fiscal years ended March 31, 2023 and 2024 did not contain an adverse opinion or a disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope, or accounting principles, except that Baker Tilly's report as of and for the fiscal year ended March 31, 2024 contained an explanatory paragraph expressing substantial doubt about the ability of the Company to continue as a going concern. During the fiscal years ended March 31, 2023 and 2024, and the subsequent interim period through July 1, 2024, there were (i) no "disagreements," as that term is defined in Item 304(a)(1)(iv) of Regulation S-K, with Baker Tilly on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, any of which, if not resolved to Baker Tilly's satisfaction, would have caused it to make reference to the subject matter of any such disagreement in connection with its reports for such fiscal years and (ii) no "reportable events," as that term is defined in Item 304(a)(1)(v) of Regulation S-K, during the fiscal years ended March 31, 2023 and 2024 requiring disclosure pursuant to paragraph (a)(1)(v) of Item 304 of Regulation S-K and the related instructions to Item 304 of Regulation S-K. In accordance with Item 304(a)(3) of Regulation S-K, the Company provided Baker Tilly with a copy of this Current Report prior to its filing with the Securities and Exchange Commission ("SEC")
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 16.1 Letter from Baker Tilly US, LLP to the Securities and Exchange Commission, dated July 3, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 3, 2024 Aethlon Medical, Inc. By: /s/ James B. Frakes Name: James B. Frakes Interim Chief Executive Officer and Chief Financial Officer 3